格隆汇1月4日丨之江生物(688317.SH)公布，截至2025年12月31日，公司通过上海证券交易所交易系统 以集中竞价交易方式累计回购公司股份181.29万股，占公司当前总股本192,157,999股的比例为0.94%， 回购成交的最高价为22.86元/股，最低价为19.58元/股，支付的资金总额为人民币39,130,207.59元(不含 印花税、交易佣金等交易费用)。 ...

格隆汇1月4日丨之江生物(688317.SH)公布，截至2025年12月31日，公司通过上海证券交易所交易系统 以集中竞价交易方式累计回购公司股份181.29万股，占公司当前总股本192,157,999股的比例为0.94%， 回购成交的最高价为22.86元/股，最低价为19.58元/股，支付的资金总额为人民币39,130,207.59元(不含 印花税、交易佣金等交易费用)。 ...

证券代码：688317 证券简称：之江生物 公告编号：2026-001 上海之江生物科技股份有限公司 关于 2025 年第三次以集中竞价交易方式回购公司股份 的进展公告 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，应当在每个月的前 3 个交易日内公告截至上月末 的回购进展情况。现将公司回购股份进展情况公告如下： 2025 年 12 月，公司通过上海证券交易所交易系统以集中竞价交易方式累计回 购公司股份 719,230 股，占公司当前总股本 192,157,999 股的比例为 0.37%，回购 成交的最高价为 21.99 元/股，最低价为 19.58 元/股，支付的资金总额为人民币 14,969,293.46 元（不含印花税、交易佣金等交易费用）。 截至 2025 年 12 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 1,812,934 股，占公司当前总股本 192,157,999 股的比例 为 0.94%，回购成交的最高价为 22.86 元/股，最低价为 19.58 元/股，支付的资金 总额为 ...

证券代码：688317 证券简称：之江生物 公告编号：2026-002 上海之江生物科技股份有限公司 关于部分募集资金账户注销的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 在募集资金存放及使用期间，公司严格按照《募集资金专户存储三方监管协 议》履行义务，"体外诊断试剂生产线升级项目"已终止，并将尚未投入的部分 募集资金及募集资金累计利息收入、现金管理收益用于新增募投项目"日本智能 化制造项目"的建设及调增"产品研发项目"的投资金额，上述项目募集资金专 户将不再使用，具体情况详见公司在上海证券交易所网站（www.sse.com.cn）披 露的《关于公司部分募投项目变更的公告》（公告编号：2025-048）。为了便于 对募集资金专用账户进行管理，公司决定对上述项目募集资金账户予以注销，注 销情况如下： 二、募集资金管理情况 为规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者利益， 公司根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司募集 资金监管规则》《上海证券交易所科创板上市公司自律监管指引 ...

Group 1 - The core viewpoint of the news is that Zhijiang Biotech's stock has shown a slight increase of 1.07%, reaching a price of 19.87 CNY per share, with a total market capitalization of 3.818 billion CNY [1] - Zhijiang Biotech, established on April 18, 2005, specializes in the research, production, and sales of molecular diagnostic reagents and equipment, with a significant revenue contribution from nucleic acid testing kits at 86.47% [1] - The company's revenue breakdown indicates that other products account for 11.99%, while molecular diagnostic instruments contribute 1.54% [1] Group 2 - Among the top circulating shareholders of Zhijiang Biotech, Dazhong Fund's Dazhong Jingheng Mixed A (090019) holds 909,200 shares, representing 0.47% of the circulating shares, with no change in the number of shares held compared to the previous period [2] - Dazhong Jingheng Mixed A has achieved a year-to-date return of 41.96% and a one-year return of 37.38%, ranking 1840 out of 8087 and 2005 out of 8085 in its category, respectively [2] - The fund manager, Su Bingyi, has a tenure of 13 years and 329 days, with the fund's total asset size at 1.9 billion CNY and a best return of 250.69% during his management period [2]

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

Core Viewpoint - Zhijiang Biological announced the appointment of Zhonghui Certified Public Accountants as the auditing firm for the company's 2025 financial statements and internal controls, with changes in the assigned auditors due to personnel adjustments [1] Group 1 - Zhonghui Certified Public Accountants will provide auditing services for the 2025 fiscal year [1] - Liu Muyong was originally appointed as the project partner, with Wang Xuefen and Liu Muyong as signing auditors, and Wu Xiaohui as the quality control reviewer [1] - Due to Wang Xuefen's departure from Zhonghui and internal adjustments, Zhu Qi has been appointed as the signing auditor, and Shi Weicen as the quality control reviewer [1]

证券代码：688317 证券简称：之江生物 公告编号：2025-069 上海之江生物科技股份有限公司 关于变更签字注册会计师及项目质量控制复核人的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海之江生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第五届董事会第十三次会议，并于 2025 年 5 月 15 日召开 2024 年年度股 东大会，审议通过了《关于续聘 2025 年度审计机构的议案》，同意公司续聘中 汇会计师事务所（以下简称"中汇"）作为公司 2025 年度审计机构，聘期一年。 具体内容详见公司于 2025 年 4 月 25 日在上海证券交易所网站（www.sse.com.cn） 刊载披露的《关于续聘 2025 年度会计师事务所的公告》（公告编号：2025-028）。 近日，公司收到中汇出具的《关于变更签字会计师及质量控制复核人的告知 函》，现就具体情况公告如下： 一、本次签字会计师及质量控制复核人变更情况 中汇为公司 2025 年度财务报表和内部控制的审计机构，原委派刘木 ...

Core Viewpoint - Zhijiang Bio's Japanese smart manufacturing project is progressing smoothly and has not been directly affected by changes in the external policy environment [1] Group 1: Project Status - The Japanese smart manufacturing project is being advanced in an orderly manner [1] - The company is closely monitoring the dynamics of Sino-Japanese relations and regional situations [1] Group 2: Operational Principles - The company adheres to principles of prudent operation and risk control during project decision-making and implementation [1] - Future evaluations and responses will be based on changes in the situation to ensure smooth project progress and protect shareholder interests [1]

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].